Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population - Takeaways - MDSpire

Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population

  • By

  • Po-Fan Hsieh

  • Wei-Juan Li

  • Wei-Ching Lin

  • Han Chang

  • Chao-Hsiang Chang

  • Chi-Ping Huang

  • Chi-Rei Yang

  • Wen-Chi Chen

  • Yi-Huei Chang

  • Hsi-Chin Wu

  • August 22, 2019

  • 0 min

Share

  • 1

    Prostate cancer incidence is rising in Asia, particularly in Eastern countries, influenced by Westernized diets and improved cancer registration.

  • 2

    PSA screening has low accuracy for clinically significant prostate cancer, with a positive predictive value of only 32%.

  • 3

    The prostate health index (PHI) shows promise as a biomarker, outperforming traditional PSA tests and reducing unnecessary biopsies.

  • 4

    Multiparametric MRI (mpMRI) effectively identifies suspicious lesions, allowing 27% of patients to avoid unnecessary prostate biopsies.

  • 5

    This study evaluates the combination of PHI and mpMRI for detecting clinically significant prostate cancer in an Asian population.

Original Source(s)

Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population

  • by Po-Fan Hsieh, Wei-Juan Li, Wei-Ching Lin, Han Chang, Chao-Hsiang Chang, Chi-Ping Huang, Chi-Rei Yang, Wen-Chi Chen, Yi-Huei Chang, Hsi-Chin Wu

  • August 22, 2019

Related Content

Miniaturised ultrasound evaluation at the bedside

Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores

Predicting invasiveness and disease-specific survival in upper tract urothelial carcinoma: identifying relevant clinical tumour characteristics